TriangleNCT01535040 · OUTCOME
Nicotine Dependence
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- LEAST_SQUARES_MEAN
- Unit
- units on a scale
- Interval / dispersion
- Standard Error
- Time frame
- 12 weeks
What was measured
The Fagerstrom tolerance scale consists of 8 questions, each of which is scored on a 0 to 1 or 0 to 2 scale. The total score ranges from 0 to 11, with higher scores representing greater dependence.
Analysis population: Participants who reported any data
Groups in this outcome
Arm I - Memantine
Participants receive memantine hydrochloride PO BID) on days 1-81 in the absence of unacceptable toxicity. memantine hydrochloride: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
Arm II - Placebo
Participants receive a placebo PO BID on days 1-81 in the absence of unacceptable toxicity. placebo: Placebo by mouth through completion of 12 weeks.
| Group | Source count |
|---|---|
| Arm I - Memantine | 64 |
| Arm II - Placebo | 65 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm I - Memantine | 5.29 | 0.30 | Not reported | Not reported | Not reported |
| Arm II - Placebo | 4.83 | 0.28 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 0.30
- value
- 5.29
- group Id
- OG001
- spread
- 0.28
- value
- 4.83
- denoms
- counts
- group Id
- OG000
- value
- 64
- group Id
- OG001
- value
- 65
- units
- Participants
- description
- The Fagerstrom tolerance scale consists of 8 questions, each of which is scored on a 0 to 1 or 0 to 2 scale. The total score ranges from 0 to 11, with higher scores representing greater dependence.
- dispersion Type
- Standard Error
- groups
- description
- Participants receive memantine hydrochloride PO BID) on days 1-81 in the absence of unacceptable toxicity. memantine hydrochloride: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
- id
- OG000
- title
- Arm I - Memantine
- description
- Participants receive a placebo PO BID on days 1-81 in the absence of unacceptable toxicity. placebo: Placebo by mouth through completion of 12 weeks.
- id
- OG001
- title
- Arm II - Placebo
- param Type
- LEAST_SQUARES_MEAN
- population Description
- Participants who reported any data
- reporting Status
- POSTED
- time Frame
- 12 weeks
- title
- Nicotine Dependence
- type
- SECONDARY
- unit Of Measure
- units on a scale
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice